State of the Art Technology Coupled with Excellent Performance
Patient Management through Molecular Diagnostic Solution
Hematogenix Laboratory Services offers a wide array of molecular diagnostic tests to facilitate patient-care through responsible and collaborative decision-making. Our assays are validated in-house to ensure the highest level of quality and superb patient outcome.
Polymerase Chain Reaction – PCR
PCR is a technique that is widely utilized in molecular biology to amplify a single copy of DNA strand into million of copies, thus making it an excellent method of choice for identifying target material(s) from limited amount of samples. This method is highly sensitive and specific.
Molecular assay by PCR is an excellent choice for testing patient samples to investigate and identify underlying medical condition, confirm existing clinical or other laboratory findings, and identify patients responsiveness to certain medications. Stratifying patients who are likely to benefit from certain drugs can significantly improve patient outcome, avoid unnecessary risks and costs.
Real-Time Polymerase Chain Reaction – RT-PCR
RT-PCR is used to amplify and simultaneously detect or quantify a targeted nucleic acid molecule in a biological sample of interest. RT-PCR eliminates subjectivity while improves sensitivity and precision
Some of Our Molecular Testing Options
Lineage Determination of Leukemias and Lymphomas
B-Cell Gene Clonality Assay: Identify clonal B-cell populations highly suggestive of B-cell malignancies.
T-Cell Gene Clonality Assay: Identify clonal T-cell populations highly suggestive of T-cell malignancies.
Myeloproliferative Neoplasms (MPNs)
JAK2 V617F allele discrimination assay: PV, ET, and PMF
MPL W515L/K: ET and PMF on JAK2 V6167F negative patients
Chronic Myeloproliferative Leukemia (CML)
BCR-ABL Assay, Quantitative: Use to diagnose patients with CML and monitor response to tyrosine kinase inhibitor (TKI) such as Imatinib.
Solid Tumor Markers Evaluation
KRAS: FDA approved companion diagnostic assay essentially critical in identifying colorectal cancer patients who are most likely to respond to anti-epidermal growth factor receptor such as panitumumab or Ertibux® (cetuximab).
EGFR: FDA approved companion diagnostic assay that identify NSCLC EGFR mutation-positive patients who most likely respond to EGFR directed TKI such as GILOTRIFTM (afatinib).
BRAF: FDA approved companion diagnostic assay that can identify melanoma cancer patients eligible for treatment with BRAF inhibitor therapy drugs such as Dabrafenib and Trametinib.
Click here to download our Specimen Requirements Sheet.
Click here to download our Test Offering Quick Reference Sheet.
Check again soon for our comprehensive test offering index.